Global House Dust Mite Allergy Market Analysis & Outlook 2018-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “House
Dust Mite Allergy – Market Insights, Epidemiology and Market Forecast”

drug pipelines has been added to ResearchAndMarkets.com’s
offering.

In 2016, global market size of House Dust Mite Allergy was USD 258
million and is expected to grow during the forecast period of 2018-2027.

Odactra by Merck Sharp & Dohme Corp. and Actair by Shionogi & Co. are
currently approved therapies for House Dust Mite Allergies.

The disease epidemiology covered in the report is segmented into two
parts: Total Prevalent Population of Respiratory Allergy and Total
Prevalence of House Dust Mite (HDM) Induced Respiratory Allergies in 7
Major Markets [United States and EU5 (Germany, Spain, Italy, France and
United Kingdom) and Japan].

According to the report, the prevalent cases of House Dust Mite Induced
Respiratory Allergy was 50,703,100 in 2016 in 7MM and, is expected to
increase during the study period i.e., 2016-2027. Among 7MM, United
States account for highest prevalent cases of House Dust Mite Allergy
with 69,310,852 prevalent cases in 2016.

Report Coverage

This report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology trends in the United States, EU5
(Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs,
market share of the individual therapies, current and forecasted market
size of House Dust Mite Allergy from 2016 to 2027 segmented by the US,
EU-5 countries and Japan.

The report also covers current treatment practice/algorithm, market
drivers, market barriers and unmet medical needs to curate best of the
opportunities and assess underlying potential of the market.

Companies Featured

  • Merck Sharp & Dohme Corp.
  • Shionogi & Co.

Key Topics Covered

1. Key Insights

2. House Dust Mite Allergy Market Overview at a Glance

3. House Dust Mite Allergy: Disease Background and Overview

4. Epidemiology and Patient Population

5. 7MM Total Prevalence of HDM Induced Respiratory Allergy

6. Country Wise-Epidemiology of House Dust Mite Allergy

7. Unmet Needs

8. Marketed Drug Analysis

9. House Dust Mite Allergy: 7 Major Market Analysis

10. The United States Market Outlook

11. EU-5 Countries: Market Outlook

12. Market Drivers

13. Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/97gp3s/global_house_dust?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Allergy
Drugs

leverton

I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.